Table 1.
Associations between receiving Chronic Myeloid Leukemia (CML) treatment initiation and patient characteristics
|
Characteristics |
1998a |
2004 |
2007 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
n (%) |
χ2 |
OR |
p |
n (%) |
χ2 |
OR |
p |
n (%) |
χ2 |
OR |
p |
| (p-value) | (95%CI)b | (p-value) | (95%CI) | (p-value) | (95%CI) | |||||||
|
Age at diagnosis, years | ||||||||||||
| ≥40 |
228 (81.1) |
9.16 (<0.01) |
0.4 (0.2-0.8) |
<0.01 |
160 (74.4) |
6.30 (0.01) |
0.5 (0.2-0.9) |
0.03 |
186 (72.1) |
16.86 (<.0001) |
0.4 (0.2-0.7) |
<0.01 |
| <40 |
53 (18.9) |
|
1 (referent) |
|
55 (25.6) |
|
1 (referent) |
|
72 (27.9) |
|
1 (referent) |
|
|
Gender | ||||||||||||
| Male |
166 (59.1) |
0.00 (0.95) |
0.8 (0.4-1.7) |
0.60 |
126 (58.6) |
1.25 (0.26) |
0.7 (0.4-1.3) |
0.26 |
151 (58.5) |
0.49 (0.49) |
1.4 (0.8-2.3) |
0.29 |
| Female |
115 (40.9) |
|
1 (referent) |
|
89 (41.4) |
|
1 (referent) |
|
107 (41.5) |
|
1 (referent) |
|
|
Charlson comorbidity score | ||||||||||||
| ≥1 |
101 (35.9) |
0.00 (0.97) |
1.2 (0.6-2.4) |
0.71 |
118 (54.9) |
3.71 (0.05) |
0.6 (0.4-1.2) |
0.13 |
140 (54.3) |
20.36 (<.0001) |
0.4 (0.2-0.6) |
<0.001 |
| =0 |
180 (64.1) |
|
1 (referent) |
|
97 (45.1) |
|
1 (referent) |
|
118 (45.7) |
|
1 (referent) |
|
|
CML severity | ||||||||||||
| high severity |
45 (16.0) |
17.90 (<.0001) |
4.3 (2.0-9.3) |
<0.001 |
28 (13.0) |
1.64 (0.20) |
2.1 (0.8-5.4) |
0.12 |
40 (15.5) |
2.87 (0.09) |
2.3 (1.1-5.1) |
0.04 |
| less severityc | 236 (84.0) | 1 (referent) | 187 (87.0) | 1 (referent) | 218 (84.5) | 1 (referent) | ||||||
a. 1998 (beginning of study, n = 281); 2004 (end of prior authorization request for imatinib use, n = 215); 2007 (end of study, n = 258).
b. OR = odds ratio, each OR of the variable was adjusted by the other factors in the logistic regression model.
c. Less severity, including moderate, low severity or missing relevant severity information (unknown).